Kalo Deepika, Kant Surya, Srivastava Kanchan, Sharma Ajay K
Department of Zoology, University of Lucknow, Lucknow, Uttar Pradesh, India.
Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Lung India. 2017 Mar-Apr;34(2):155-159. doi: 10.4103/0970-2113.201314.
Tuberculosis (TB), a highly contagious disease that sees no gender, age, or race is mainly a disease of lungs. According to World Health Organization, a TB patient can be completely cured with 6-9 months of anti-TB treatment under directly observed treatment short course.
The aim of this study was to check the mono, multi- and triple-drug resistance to first line drugs (FLDs) among TB patients and to access their genetic profile using DR 3074, DR 0270, DR 0642, DR 2068, and DR 4110 using molecular techniques.
To gain a better understanding of drug resistant TB, we characterized 121 clinical isolates recovered from 159 drug resistant pulmonary tuberculosis patients by genotyping. MTB isolates recovered from HIV- negative, and smear positive cases of both genders, age varied from 18 to 70 years with drug resistant-TB that was refractory to chemotherapy given for > 12 months. Of a total of 159 sputum smear positive patients sum number of male and female patients was 121 (76.10%) and 38 (23.89%), respectively. Among these patients, number of literate and illiterate patients were 123 (77.3%) and 36 (22.6%). 25 (15.7%) patients had farming as their occupation, 80 (50.3%) had nonagricultural occupation and 54 (33.9%) women were housewives.
Mono drug resistant, multi-drug resistant, and totally drug resistant (TDR) cases of TB were calculated as 113.83%, 125.1%, and 67.9%. Isoniazid showed the highest percentage of resistance among the patients.
Any noncompliance to TB medications, lack of knowledge, and poor management in health centers, etc., results in the emergence of deadly direct repeat forms of TB, which are further complicated and complex to treat.
结核病(TB)是一种高度传染性疾病,不分性别、年龄或种族,主要是肺部疾病。根据世界卫生组织的说法,在直接观察下的短程治疗中,结核病患者通过6至9个月的抗结核治疗可以完全治愈。
本研究的目的是检查结核病患者对一线药物(FLDs)的单药、多药和三联耐药情况,并使用分子技术通过DR 3074、DR 0270、DR 0642、DR 2068和DR 4110分析其基因特征。
为了更好地了解耐药结核病,我们通过基因分型对从159例耐药性肺结核患者中分离出的121株临床菌株进行了特征分析。结核分枝杆菌分离株来自HIV阴性、涂片阳性的男女患者,年龄在18至70岁之间,患有耐药结核病,对超过12个月的化疗无效。在总共159例痰涂片阳性患者中,男性和女性患者总数分别为121例(76.10%)和38例(23.89%)。在这些患者中,识字和不识字的患者人数分别为123例(77.3%)和36例(22.6%)。25例(15.7%)患者以务农为职业,80例(50.3%)从事非农业职业,54例(33.9%)女性为家庭主妇。
结核病的单药耐药、多药耐药和完全耐药(TDR)病例分别计算为113.83%、125.1%和67.9%。异烟肼在患者中的耐药率最高。
任何对结核病药物的不依从、知识缺乏以及医疗中心管理不善等,都会导致致命的直接重复型结核病的出现,而这种类型的结核病治疗起来更加复杂和困难。